350 FIFTH AVENUE, NEW YORK, NY
Investor Presentation
Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals Adopts Severance and Change in Control Program
Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
VP of Finance John Militello Resigns; Joseph Manhede Appointed Principal Acco...
Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Stockholders Elect Seven Directors at Rocket Pharmaceuticals Annual Meeting
Q2
FY 2024
Q3
Q1
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Notification Filed by a National Security Exchange
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement